In a previous post we have briefly outlined the motivations and goals of APRA. Here, we take a more in-depth look at the principles that define APRA’s philosophy and approach. This post will hopefully provide a clearer picture of what APRA is about. Enjoy! And thanks for reading. Core Principles Research and education focus. The focus […]Read more "Core Principles"
APRA is an interdisciplinary, academic association for researchers and university students based in Amsterdam, focusing on substances that show promise for therapy and research, but that suffer an impaired research development because of their legal status or psychoactive effects.Read more "Welcome"
Isolde de Jong started her internship with APRA in November 2018, ever since she is reporting activities within the organization. As a student of applied psychology with a main interest in psychedelic research, she developed a strong curiosity in the biological mechanisms of certain entheogenic plants and other substances. With this internship she hopes to […]Read more "New realities in psychotrauma"
Our 11th JC installment will be hosted by Koen Seignette, PhD student at the Netherlands Institute for Neuroscience. Koen’s work focuses on sensory processing and plasticity, perceptual learning, feedforward and feedback integration in mouse V1, in the Christiaan Levelt Lab. Where: Vrije Universiteit Amsterdam, Medical Faculty Building, Room D565 When: Tuesday, May 21st, 6pm (presentation […]Read more "Journal Club #11 – Koen Seignette (PhD cand.): “Feedback-feedforward information processing unbalances and the neurophysiology of hallucinations”"
This symposium discusses research into the therapeutic use of MDMA, both historically and presently.Read more "Opening Up [Symposium] – Shaping the future: therapeutic applications of MDMA"
Considerations on Esketamine for Depression by Ivar Rambags, Marco Aqil, and Jennifer Them Back in 1956, ketamine was originally derived from phencyclidine as a shorter acting analogue with less delirious side effects . By then still known as CI-581, ketamine’s first clinical results were published by Corssen and Domino in 1966 and revealed itself to […]Read more "Considerations on Esketamine for Depression"
Join us for a unique talk held by, Thijs Roes, where he will discuss “The War On Drugs; why it was started, how it evolved, and what we can do to end it” (Facebook event). Thijs Roes is a science journalist who has worked across Europe and the United States extending reach on projects concerning […]Read more "Journal Club #10 – Thijs Roes: “The War on Drugs”"
There is renewed interest in the application of psychedelics in psychiatric care. This trial is the first that examines the safety and efficacy of psilocybin-treatment at a larger scale in participants with treatment resistant depression. We are joined by Renske Blom, resident psychiatry, MD (Sub-I of the psilocybin study) and Metten Somers, psychiatrist, MD , […]Read more "Psilocybin Treatment in Patients with Treatment-Resistant Depression – Lecture by Renske Blom (MD) and Metten Somers (MD, PhD)"
Isolde de Jong started her internship with APRA in November 2018, ever since she is reporting activities within the organization. As a student of applied psychology with a main interest in psychedelic research, she developed a strong curiosity in the biological mechanisms of certain entheogenic plants and other substances. With this internship she hopes to […]Read more "Destigmatizing Ketamine – an Interview with Tharcila Chaves"